Product Name: KinSub1DDLYF
Product Number: PE-01AGP95
Size: 200 µg      Price:99.00
      $US
Peptide Name: KinSub1DDLYF

Product Use: For assaying the phosphotransferase activity of NT-3 growth factor receptor (TrkC, UniProt ID Q16288). The KinSub1DDLYF peptide demonstrated very high phosphotransferase activity with Brk, and exhibited moderate specificity when assayed with over 200 other protein kinases. A listing of other kinases that show appreciable phosphotransferase activity towards this peptide are listed in Table 1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: KinSub1DDLYF was originally identified using a microarray with peptides that were predicted as optimal substrates for 500 human protein kinases with a proprietary algorithm developed at Kinexus with our academic partners.

Peptide Sequence: GGGEDDLYFGPGGGG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1353 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: Brk

Scientific Background: TrkC is one of several protein kinases that can phosphorylate KinSub1DDLYF. Human TrkC is a receptor protein-tyrosine kinase of 839 amino acid length, with a predicted molecular mass of 94,428 Da. It is a member of the TK group of protein kinases in the Trk family. This kinase shows high variability in human tissue distribution with the highest levels detected in brain, liver, spinal cord and thymus. Orthologues of TrkC are highly conserved in mammals and birds. It is the high affinity catalytic receptor for the neurotrophin NT-3. TrkC is activated by phosphorylation at Y516. Phosphorylation of Y834 of TrkC induces interaction with PLCg1 and Shc1. TRKC mediates the multiple cellular effects of the NT-3 neurotrophic factor, which includes neuronal differentiation and survival (1). TrkC has been implicated in insulin signalling pathway through interactions with the MUSK protein receptor and the VEGF receptor. Mutations in the TrkC gene have been associated with medulloblastomas, secretory breast carcinomas and other cancers (2). TrkC has also been linked with the development of pediatric mesenchymal, colon, and large lung cell carcinomas (LLCC), and gastric and lung adenocarcinomas.